The Wall Street Journal: CureVac says COVID-19 vaccine was 48% effective in key study

This post was originally published on this site

German company CureVac

released the final results for its once-promising Covid-19 vaccine, finding it provided less protection than the vaccines already authorized for use in the U.S.

The company said Wednesday that its vaccine was 48% effective in providing protection against Covid-19 of any severity, regardless of age, in a large, pivotal study.